Introduction
In the field of pharmacy, the relationship between healthcare professionals and pharmaceutical companies has long been a topic of scrutiny, particularly regarding its influence on prescribing practices and medication costs. This essay draws on the article “Leachon bares doc-pharma firms ‘collusion’ in prescribing meds” (Parungao, 2024), which exposes alleged schemes in the Philippines where doctors receive luxury perks, such as cars and travel, in exchange for prescribing specific medications, often unnecessarily. From the perspective of a pharmacy student, this discussion highlights the broader implications for global healthcare systems, including in the UK. The essay addresses three key questions: how such collusion affects medication prices, the consequences of prescribing unnecessary medications for patients, and the ethical considerations medical professionals should prioritise. Additionally, it relates these issues to the Netflix series Painkiller, which dramatises similar unethical practices in the pharmaceutical industry. Through analysis supported by academic sources, this essay argues that exposed prescribing behaviours not only inflate medication prices but also undermine patient trust and healthcare equity, calling for stronger regulatory oversight.
Collusion Between Doctors and Pharmaceutical Companies and Its Effect on Medication Prices
Collusion between doctors and pharmaceutical companies, as alleged in the Leachon article, directly contributes to inflated medication prices by distorting market dynamics and encouraging over-prescription. In the described schemes, pharmaceutical firms reportedly recruit doctors with quotas tied to sales volumes, rewarding them with extravagant incentives (Parungao, 2024). This practice shifts the focus from patient needs to profit motives, leading to a higher demand for branded or expensive drugs that may not be the most cost-effective options.
From a pharmacy perspective, such arrangements exacerbate price inflation through several mechanisms. Firstly, doctors influenced by these perks are more likely to prescribe higher-cost medications, bypassing cheaper generics. A study by the World Health Organization (WHO) notes that unethical marketing practices, including gifts to prescribers, can increase drug prices by up to 20-30% in low- and middle-income countries, as companies recoup the costs of incentives through elevated pricing (WHO, 2019). In the UK context, similar influences have been observed, where pharmaceutical detailing—direct marketing to doctors—correlates with prescribing more expensive drugs, contributing to the National Health Service (NHS) spending over £9 billion annually on medicines, with unnecessary prescriptions adding to this burden (NHS Digital, 2022). Indeed, when collusion is exposed, as in the Leachon case, it can lead to public backlash and regulatory scrutiny, potentially forcing price reductions or market withdrawals. However, without intervention, these behaviours sustain high prices, as companies maintain monopolistic control over prescriptions.
Furthermore, this collusion limits competition from generic alternatives. Research indicates that physician-targeted incentives reduce the uptake of generics, which are typically 80-85% cheaper than branded equivalents (Wazana, 2000). As a pharmacy student, I observe that in community pharmacies, this results in patients facing higher out-of-pocket costs or straining public health budgets. The exposure of such practices, like Leachon’s revelations, arguably pressures companies to justify pricing, but the immediate impact is often a short-term spike in costs due to shifts in prescribing patterns. Overall, this underscores the need for transparent pricing models to mitigate these effects.
Consequences of Doctors Prescribing Unnecessary Medication for Patients
The prescription of unnecessary medications, driven by collusion as highlighted in the article, poses significant risks to patients, ranging from financial strain to adverse health outcomes. Leachon emphasises that patients receive drugs they do not need, which may be of questionable quality or efficacy, leading to inflated expenses and potential harm (Parungao, 2024). This not only victimises patients but also erodes the foundational trust in healthcare systems.
One primary consequence is the financial burden on patients. Unnecessary prescriptions increase healthcare costs, with studies showing that over-prescribing contributes to wasteful spending. For instance, in the UK, the NHS estimates that avoidable medication errors and unnecessary prescriptions cost approximately £98.5 million per year, often resulting in higher prices passed on to patients or taxpayers (Elliott et al., 2020). Patients may face polypharmacy—taking multiple drugs—leading to non-adherence due to cost, which can worsen health conditions. From a pharmacy student’s viewpoint, dispensing such medications often involves counselling patients on affordability, highlighting how collusion indirectly drives up prices through sustained demand for non-essential drugs.
Health risks are equally concerning. Prescribing ineffective or unnecessary medications can cause adverse effects, such as drug interactions or side effects, without therapeutic benefits. Leachon notes that “the worst product is the product that does not work,” aligning with evidence from systematic reviews that over-prescription increases the incidence of antibiotic resistance and other iatrogenic harms (Ventola, 2015). For vulnerable groups, like the elderly, this can lead to hospitalisations, further escalating costs. Moreover, psychological impacts include diminished confidence in medical advice, potentially deterring patients from seeking necessary care. In essence, these consequences amplify medication prices by necessitating additional treatments to address complications, creating a vicious cycle of expenditure and harm.
Ethical Considerations for Medical Professionals Interacting with Pharmaceutical Companies
Medical professionals must prioritise ethical standards when engaging with pharmaceutical companies to safeguard patient interests and maintain professional integrity. The Leachon article prompts reflection on these issues, especially following the Philippine Department of Health’s circular deeming gifts unethical (Parungao, 2024). Key considerations include beneficence, non-maleficence, and justice, as outlined in medical ethics frameworks.
Primarily, professionals should ensure patient welfare supersedes financial gains. The General Medical Council (GMC) in the UK mandates that doctors avoid conflicts of interest, stating that “you must not ask for or accept any inducement, gift or hospitality which may affect or be seen to affect the way you prescribe” (GMC, 2013). This aligns with ethical codes emphasising transparency; failing to disclose ties can lead to biased prescribing, inflating prices and harming patients. As a pharmacy student, I recognise that pharmacists also play a role in ethical dispensing, often questioning prescriptions influenced by marketing.
Additionally, justice requires equitable access to affordable medications. Interactions should not favour expensive drugs over generics, as this disadvantages low-income patients. Research from the British Medical Journal highlights that ethical lapses in pharma-doctor relationships contribute to health inequalities, with price hikes disproportionately affecting marginalised groups (Godlee, 2006). Professionals should engage in evidence-based continuing education rather than sponsored events to avoid undue influence. Ultimately, prioritising these considerations fosters trust and could reduce medication prices by promoting rational prescribing.
Relation to the Netflix Series Painkiller
The issues raised in the Leachon article resonate strongly with the Netflix series Painkiller (2023), which dramatises the opioid crisis in the United States, focusing on Purdue Pharma’s aggressive marketing of OxyContin. The series illustrates how pharmaceutical companies used incentives, including lavish perks for doctors, to boost prescriptions, mirroring the collusion described by Leachon (Parungao, 2024). In Painkiller, sales representatives targeted physicians with gifts and quotas, leading to widespread over-prescription of opioids, which inflated drug prices and contributed to addiction epidemics.
This connection highlights the global nature of such practices; while Leachon’s allegations are set in the Philippines, Painkiller exposes similar tactics in the US, where OxyContin’s pricing soared due to manufactured demand, costing the healthcare system billions (Van Zee, 2009). As a pharmacy student, viewing the series underscores the human cost of unethical prescribing, reinforcing the need for vigilance in monitoring pharma influences to prevent price escalations and patient harm.
Conclusion
In summary, the exposed prescribing behaviours in the Leachon article demonstrate how doctor-pharma collusion inflates medication prices through over-prescription and reduced generic uptake, while imposing severe financial and health consequences on patients. Ethical priorities, such as patient-centred care and transparency, are essential to counteract these issues. The parallels with Painkiller emphasise the urgency of reform. For pharmacy students and professionals, this calls for advocating stricter regulations, like enhanced UK guidelines, to ensure affordable, ethical healthcare. Addressing these challenges could lead to more equitable systems, reducing unnecessary costs and restoring public trust. Ultimately, exposing such practices serves as a catalyst for positive change in global pharmacy.
References
- Elliott, R.A., Camacho, E., Jankovic, D., Sculpher, M.J. and Faria, R. (2020) Economic analysis of the prevalence and clinical and economic burden of medication error in England. BMJ Quality & Safety, 30(2), pp.96-105.
- General Medical Council (GMC). (2013) Good medical practice. GMC.
- Godlee, F. (2006) Doctors and the drug industry. British Medical Journal, 332(7536), p.0.
- NHS Digital. (2022) Prescribing costs in hospitals and the community: England 2021/22. NHS Digital.
- Parungao, A. (2024) Leachon bares doc-pharma firms ‘collusion’ in prescribing meds. INQUIRER.net, 23 April. Available at: https://newsinfo.inquirer.net/1935120/leachon-bares-doc-pharma-firms-collusion-in-prescribing-meds (Accessed: 24 April 2024).
- Van Zee, A. (2009) The promotion and marketing of oxycontin: Commercial triumph, public health tragedy. American Journal of Public Health, 99(2), pp.221-227.
- Ventola, C.L. (2015) The antibiotic resistance crisis: Part 1: Causes and threats. P&T: A Peer-Reviewed Journal for Formulary Management, 40(4), pp.277-283.
- Wazana, A. (2000) Physicians and the pharmaceutical industry: Is a gift ever just a gift? JAMA, 283(3), pp.373-380.
- World Health Organization (WHO). (2019) WHO guideline on country pharmaceutical pricing policies. WHO.
